search
Back to results

Diphenhydramine for Acute Migraine

Primary Purpose

Migraine

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
metoclopramide
diphenhydramine
placebo
Sponsored by
Montefiore Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Migraine focused on measuring migraine, headache, metoclopramide, diphenhydramine

Eligibility Criteria

21 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Acute migraine headache
  • Present to our emergency room in the Bronx, NY for treatment of migraine headache

Exclusion Criteria:

  • Temperature > 100.3 F
  • Pheochromocytoma
  • Seizure disorder
  • Parkinson's disease
  • Use of monoamine oxidase (MAO) inhibitors
  • Use of anti-rejection transplant medications
  • Use of potassium supplements
  • Use of pramlintide

Sites / Locations

  • Montefiore Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Metoclopramide + Diphenhydramine

Metoclopramide + placebo

Arm Description

Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes

Metoclopramide 10mg + placebo, administered intravenously over 15 minutes

Outcomes

Primary Outcome Measures

Number of Participants With Sustained Headache Relief Assessed by Self-evaluation
Sustained headache relief is defined as achieving a headache level of "mild" or "none" within two hours and maintaining a level of "mild" or "none" for 48 hours. Patient self-evaluated pain level is solicited every half hour for two hours in the Emergency Department and then by telephone 48 hours after discharge from emergency department

Secondary Outcome Measures

Full Information

First Posted
April 2, 2013
Last Updated
July 2, 2018
Sponsor
Montefiore Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01825941
Brief Title
Diphenhydramine for Acute Migraine
Official Title
Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Montefiore Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Parenteral diphenhydramine is commonly used as adjuvant therapy for acute migraine despite the fact that data supporting this practice do not exist. The investigators propose a randomized double blind study to test the hypothesis that 50mg of intravenous diphenhydramine, when added to standard migraine therapy, will result in a greater rate of sustained headache relief than standard migraine therapy alone. For this study, standard migraine therapy will be 10mg of intravenous metoclopramide. Sustained headache relief is defined as achieving a headache level of "mild" or "none" within two hours and maintaining a level of "mild" or "none" for 48 hours. Patients who present to the Montefiore emergency room (Bronx, NY) with an acute migraine will be approached for participation. They will be screened for medication contra-indications and non-migraine etiologies of headache. The study will be randomized. Assignment will be concealed. Participants and researchers will be blinded. Efficacy outcomes and adverse events will be assessed every half hour for two hours in the Emergency Department and by telephone 48 hours after medication administration. A sample size calculation, based on pilot data, revealed the need for 374 participants. An interim analysis will be performed after 200 participants have been enrolled with the goal of assessing for lack of conditional power.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine
Keywords
migraine, headache, metoclopramide, diphenhydramine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
208 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Metoclopramide + Diphenhydramine
Arm Type
Active Comparator
Arm Description
Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes
Arm Title
Metoclopramide + placebo
Arm Type
Placebo Comparator
Arm Description
Metoclopramide 10mg + placebo, administered intravenously over 15 minutes
Intervention Type
Drug
Intervention Name(s)
metoclopramide
Other Intervention Name(s)
Reglan
Intervention Description
10 milligrams, administered intravenously over 15 minutes
Intervention Type
Drug
Intervention Name(s)
diphenhydramine
Other Intervention Name(s)
Benadryl
Intervention Description
50 milligrams, administered intravenously over 15 minutes
Intervention Type
Drug
Intervention Name(s)
placebo
Primary Outcome Measure Information:
Title
Number of Participants With Sustained Headache Relief Assessed by Self-evaluation
Description
Sustained headache relief is defined as achieving a headache level of "mild" or "none" within two hours and maintaining a level of "mild" or "none" for 48 hours. Patient self-evaluated pain level is solicited every half hour for two hours in the Emergency Department and then by telephone 48 hours after discharge from emergency department
Time Frame
up to 2 hours in Emergency Department, 48 hours after discharge from Emergency Department

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Acute migraine headache Present to our emergency room in the Bronx, NY for treatment of migraine headache Exclusion Criteria: Temperature > 100.3 F Pheochromocytoma Seizure disorder Parkinson's disease Use of monoamine oxidase (MAO) inhibitors Use of anti-rejection transplant medications Use of potassium supplements Use of pramlintide
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Benjamin W Friedman
Organizational Affiliation
Montefiore Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
26320523
Citation
Friedman BW, Cabral L, Adewunmi V, Solorzano C, Esses D, Bijur PE, Gallagher EJ. Diphenhydramine as Adjuvant Therapy for Acute Migraine: An Emergency Department-Based Randomized Clinical Trial. Ann Emerg Med. 2016 Jan;67(1):32-39.e3. doi: 10.1016/j.annemergmed.2015.07.495. Epub 2015 Aug 29.
Results Reference
derived

Learn more about this trial

Diphenhydramine for Acute Migraine

We'll reach out to this number within 24 hrs